The First Affiliated Hospital of Guangzhou Medical University
In China it was confirmed that 150mg Erlotinib was effective in NSCLC patients wtih EGFR mutation, but reducing dose occurring in some patients because of the drug related side-effects. Thus, we sought to investigate that in Chinese patients with EGFR mutation whether low dose (100mg) Erlotinib had similar efficacy but lower toxcities compared with standad dose (150mg) Erlotinib.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Histological diagnosis of NSCLC with phase IIIB or IV disease;